We have investigated the effects on breast cancer cell growth of 4-hydroxytamoxifen (4OHT), a conventional antioestrogen with agonist activity, and 7m- [9-(4,4,5,5,5-pentafluoropentyhlulphinyl) 
1,3,5,(10)-triene-3,17-diol (IC] 182780), a novel, pure antiocstrogen, using established human breast cancer cell lines and cancer cells obtained directly from breast cancer patients with malignant pleural effusions who had relapsed on tamoxifen. The effects of the two agents were assessed using the Courtenay-Mills clonogenic assay, which measures the growth of single cancer cells as colonies suspended in soft agar. The standard assay was modified by the use of defined serum-and phenol red-free growth medium. The growth of oestrogen receptor (ER)-positive MCF-7 cells in the assay was oestrogen responsive. Both antioestrogens inhibited the stimulatory effects of I nrm oestradiol, but ICI 182780 caused significantly greater inhibition than 40HT at 0.1 -1.0 jom concentrations. In the absence of oestradiol, 40HT but not ICI 182780 caused significant stimulation of colony formation at low (0.01 -1.00 nM) concentrations. Neither antioestrogen had any effects on colony formation by the ER-negative Hs578T cell line. Successful colony formation was obtained in primary cultures from six out of eight malignant effusions. Colony formation was significantly stimulated by 0.1 nm oestradiol in four cases and by 10 nm 40HT in two cases. In contrast, ICI 182780 exhibited no intrinsic stimulatory activity and significantly inhibited both oestradiol-and 40HT-stimulated cell growth. We conclude that the agonist activity of 40HT and other conventional antioestrogens may cause treatment failure in some patients by stimulating breast cancer cell growth. The new, pure antioestrogen ICI 182780 is a more potent oestrogen antagonist than 4OHT and exhibits no growth-stimulatory activity. This agent may therefore offer therapeutic advantages over conventional antioestrogens in patients with advanced breast cancer and may be effective after conventional agents have failed.
Tamoxifen is currently the first-line endocrine treatment of choice for hormone-responsive breast cancer. Although at least one-third of patients with advanced breast cancer initially respond to tamoxifen, almost all eventually relapse while on continuing treatment. The mechanisms underlying these treatment failures remain incompletely understood. While tumour progression to an endocrine-independent phenotype may explain some treatment failures, it is clear from the reported response rates to second-line endocrine therapy (Henderson, 1991 ) that a significant proportion of breast tumours remain hormone responsive after tamoxifen has failed.
Clinical evidence from studies demonstrating tumour responses to withdrawal of tamoxifen at the time of treatment failure (Canney et al., 1987; Howell et al., 1992) suggests that some patients relapse on tamoxifen because their tumours become stimulated by the agonist (oestrogenic) activity exhibited by tamoxifen and other non-steroidal antioestrogens.
These clinical findings are supported by the results of laboratory studies with established human breast cancer cell lines, showing stimulation of cell growth by tamoxifen both in vitro (Darbre et al. 1984; Reddel & Sutherland, 1984; Katzenellenbogen et al., 1987; Wakeling et al., 1989) and in vivo (Gottardis & Jordan, 1988) . However, the relevance of these experimental studies to human breast cancer may be diminished by alterations in endocrine responsiveness that immortalised breast cancer cell lines may undergo during long-term cultivation (Simon et al., 1984a) . As a consequence, established cancer cell lines may become progressively less representative of the cell population of the tumour from which they originated.
We considered that a more representative experimental model with which to examine the contribution of tamoxifen's oestrogenic activity to treatment failure might be achieved by establishing primary cultures of tumour cells taken directly from breast cancer patients at the time of relapse on tamoxifen. This would permit the effects of tamoxifen to be evaluated directly in breast cancer cells from tumours which appeared clinically to be tamoxifen resistant and compared with the effects of ICI 182780, a new steroidal antioestrogen, which appears to be a pure oestrogen antagonist with no demonstrable agonist activity (Wakeling et al., 1991) . Unfortunately, obtaining tumour cells directly from patients with advanced breast cancer is frequently impractical because many patients relapse at sites which are not readily amenable to surgical biopsy. A previous study by Simon et al. (1984b) demonstrated that primary monolayer cultures could be established successfully by using tumour cells obtained from malignant pleural effusions in patients with advanced breast cancer who had relapsed in lung or pleura. Using this technique, Simon et al. (1984b) were able to demonstrate stimulation of tumour cell proliferation by tamoxifen in cultures from four out of ten patients.
Because it may prove difficult to prevent the overgrowth of normal fibroblasts and mesothelial cells using monolayer tissue culture methods, we investigated the relative effects of the two antioestrogens using the Courtenay-Mills clonogenic assay (Courtenay & Mills, 1978) , which permits the growth of human cancer cells as colonies suspended in semi-solid culture medium without excessive growth of normal cell contaminants. For the purposes of the present study, the standard protocol of the Courtenay-Mills assay was modified by the use of serum-free growth medium, in order to optimise the culture conditions for demonstrating breast cancer cell responsiveness to oestrogens and antioestrogens.
The aims of the present study were firstly to characterise the growth of human breast cancer cells in the CourtenayMills assay under serum-free conditions, using established cell lines, and secondly to utilise the assay to investigate the effects of tamoxifen and ICI 182780 in primary cultures of breast cancer cells taken from patients with advanced breast cancer who had relapsed on tamoxifen. Cultures of cells obtained directly from pleural effusions were maintained for 4 weeks and were thus 'fed' on three occasions; on the third occasion 1 ml of medium was removed from each culture tube prior to the addition of fresh SFM.
At the end of the study period, 0.3 ml of prewarmed iodonitrotetrazolium violet (Sigma) at 0.5 mg ml-' in doubledistilled water was added to each of the tubes, which were placed in a 20% oxygen incubator for 24 h. The cultures were fixed by adding 1-2 ml of 10% formol saline and stored for short periods at 4°C prior to scoring colony forma- Preliminary studies were performed with the aim of characterising the growth of established human breast cancer cell lines in the Courtenay-Mills assay under serum-free conditions. The CFE of MCF-7 cells in serum-free conditions was evaluated, and the endocrine sensitivity of the cells in the assay was examined by assessing their responsiveness to oestradiol. The oestrogenic effects of phenol red on MCF-7 colony formation in the assay were also assessed.
Further studies evaluated the relative antioestrogenic activity of 40HT and ICI 182780 in MCF-7 cells. The potential for ICI 182780 to produce non-specific cytotoxic effects was investigated in short-term exposure studies and oestrogen reversibility experiments with MCF-7 cells. The ER dependence of the activity of oestradiol and the two antioestrogens in the Courtenay-Mills assay was investigated by evaluating the effects of these agents in ER-negative Hs578T cells.
Finally, the relative oestrogenic activities of 40HT and ICI 182780 in the assay were studied by assessing their potential to stimulate MCF-7 colony formation in the absence of other exogenous oestrogens.
Experiments using primary cultures of cells from malignant pleural effusions were used to investigate the effects of oestradiol and the two antioestrogens on cancer cells obtained from patients with advanced breast cancer at the time of disease relapse or progression on tamoxifen. The plating density employed in each experiment varied according to the yield of viable cancer cells obtained from the individual effusions. As with the cell line studies, control cultures were set up using at least two different plating densities in each experiment. The effects of fixed concentrations of oestradiol (0.1 nM) and 40HT/ICI 182780 (1O nM) were evaluated in these studies. These concentrations were selected in order to approximate the physiological/therapeutic, serum hormone/ drug levels typically observed in post-menopausal breast cancer patients.
Statistical analysis
The results for each set of eight replicate cultures were compared using non-parametric statistics. Differences in CFE between experimental conditions were analysed using the Mann-Whitney U-test for comparison of two specified conditions and the Kruskal-Wallis test for comparisons of three or more specified conditions. All statistical analyses were performed on an Apple Macintosh personal computer, using the StatView SE software program (Abacus Concepts, Berkeley, CA, USA). The null hypothesis was rejected at a probability level (P) of <0.05.
Results
Growth of standard phenol red-containing control condition was included, the median CFE of the MCF-7 cells ranged between 0.284% and 0.667%. The mean intra-assay coefficient of variation (CV) was 20.2%, and the inter-assay CV was 23.8%.
Hormone responsiveness of MCF-7 colony formation
The sensitivity of MCF-7 colony formation to oestradiol was examined by investigating the effects of a range of concentrations of oestradiol on the CFE of cells cultured in defined serum-and phenol red-free medium (SFMmF) (Figure 1 ). In addition, the oestrogenic activity of phenol red in the assay was investigated by measuring the CFE of cells grown in separate control cultures using serum-free medium containing phenol red (SFMpP). Oestradiol caused a significant and dose-dependent increase in the CFE of MCF-7 cells at all concentrations between 1 pM and 10 nM, and produced a maximal stimulatory effect at a concentration of 1 nm. The CFE of cells grown in SFMp was significantly greater than that of cells grown in SFMptF. The stimulatory effect of phenol red was found to be equivalent to that of adding oestradiol at a concentration of between 1 and 10 pM.
Relative antioestrogenic effects of ICI 182780 and 40HT
Initial studies using MCF-7 cells grown in SFMpR demonstrated that 1 JLM concentrations of 40HT and ICI 182780 consistently inhibited the stimulatory effects of 1 nM oestradiol. Both antioestrogens reduced CFE to below the level of phenol red-containing controls in these experiments, and a tendency was noted for ICI 182780 to exhibit a greater inhibitory effect on CFE than 40HT.
The relative antioestrogenic efficacy of ICI 182780 and 40HT was therefore examined in more detail using MCF-7 cells cultured in SFMmF. Escalating [Antioestrogenl (mol F-1) (Figure 3) , suggesting that no acute cytotoxicity occurred at the drug concentrations used.
Secondly, the reversibility of the antiproliferative activity of ICI 182780 in MCF-7 cells was examined by increasng the competing concentration of oestradiol. The inhibitory effects of 1 FAM ICI 182780 were found to be fully reversible by oestradiol, although only at concentrations exceeding 0.1 IIM (Figure 4 ).
Colony formation by ER-negative Hs578T cells
The ER dependence of the effects of oestradiol, 40HT and ICI 182780 on cell growth in the Courtenay-Mills assay was investigated using the ER-negative Hs578T human breast cancer cell line.
The median CFE of Hs578T cells grown in SFMp under control conditions was 1.58%, and was thus considerably higher than that of MCF-7 cells cultured under similar conditions. The addition of oestradiol either alone or in combination with the two antioestrogens produced no significant changes in the CFE of Hs578T cells ( Figure 5 ).
Agonist effects of 40HT and ICI 182780 The relative oestrogenic effects of 40HT and ICI 182780 in the Courtenay-Mills assay were evaluated using 40HT produced a biphasic effect on the CFE of MCF-7 cels, resulting in significant stimulation of colony formation at concentrations between 10 pM and 10 nM, but significant inhibition at concentrations between 0.1 and 1.0I1M compared with control cultures. In contrast, ICI 182780 produced no stimulation of colony formation at any of the drug concentrations studied. It (Hamburger & Salmon, 1977; Courtenay & Mills, 1978) . They have previously been used in the field of breast cancer research principally to study the intrinsic sensitivity of tumours to cytotoxic agents (Dittrich et al., 1985; Jones et al., 1985; Staquet et al., 1987; Von Hoff et al., 1983) or to investigate the prognostic significance of tumour clonogenicity (Smallwood et al., 1984; Dittrich et al., 1985; Nomura et al., 1989; Ottestad et al., 1989) . A small number of studies, however, have used clonogenic assays to investigate the endocrine sensitivity of established breast cancer cell lines (Goldenberg & Froese, 1982; Kodama et al., 1985; Osborne et al., 1985; Manni et al., 1991) or cancer cells obtained directly from primary or metastatic human breast tumours (Manni et al., 1985; Osborne et al., 1985; Nomura et al., 1990) .
The majority of these studies were conducted using the Hamburger-Salmon human tumour-cloning assay (Hamburger & Salmon, 1977) . However, the Courtenay-Mills clonogenic assay (Courtenay & Mills, 1978) was selected for use in the present study because it has been shown previously to yield superior CFEs in studies with breast tumours (Ottestad et al., 1988) and other human malignancies (Tveit et al., 1981) .
The standard methodology of the Courtenay-Mills assay includes the use of medium containing 15% FCS (Courtenay & Mills, 1978) . Unfortunately, the addition of serum to growth media can introduce a number of uncontrolled variables into in vitro assays which may mask the responsiveness of breast cancer cells to steroid hormones and hormone antagonists. These variables include endogenous steroid hormones and various soluble factors which appear to regulate their activity (Darbre et al., 1983; Devleeschouwer et al., 1987) . In order to optimise the Courtenay-Mills assay for the evaluation of breast cancer cell sensitivity to endocrine agents, the assay method was modified in the present study by the use of defined SFM. The SFM used was based on a formulation previously shown by Wilis and West (1991) to support the growth of human cervical cancer cells in the Courtenay-Mills assay.
Successful clonogenic growth of breast cancer cells in SFM has only been reported previously by Manni et al. (1985, 1991) using the Hamburger-Salmon assay. The present study thus represents the first demonstration of successful growth of breast cancer cells in the Courtenay-Mills clonogenic assay under serum-free conditions.
Preliminary experinents with MCF-7 cells showed that their CFE is linear over a range of plating densities and demonstrated acceptable levels of intra-and inter-assay variability. In addition, these experiments confirmed that the growth of the MCF-7 cells in the Courtenay-Mills assay is hormone responsive, as shown by the dose-dependent stimulation of CFE by oestradiol. Although the oestrogen sensitivity of MCF-7 cells in monolayer culture has been well established since first reported by Lippman et al. (1976) , there appears to have been no previous reports of the effects of oestrogen on breast cancer cells cultured using the Courtenay-Mills clonogenic assay. In a previous study using the Hamburger-Salmon assay, Manni et al. (1991) demonstrated stimulatory effects of oestradiol in MCF-7 cells cultured in SFM similar to those seen in the present study.
The oestrogen sensitivity of the MCF-7 cells was demonstrable in the present study despite the presence in the growth medium of a number of supplements that have been shown to improve the clonogenicity of human tumours and which might therefore have potentially masked the stimulatory effects of oestradiol. These include epidermal growth factor (Pathak et al., 1982) , hydrocortisone and insulin (Hug et al., 1984; Kern et al., 1984) and transferrin (Calvo et al., 1983 (Berthois et al., 1986; Welshons et al., 1988) . These findings emphasise the importance of excluding phenol red from the culture conditions when undertaking in vitro studies to examine the activity of other potential weak oestrogens such as tamoxifen.
Investigation of the relative antioestrogenic activity of 40HT and ICI 182780 in the present study demonstrated that ICI 182780 acted as a more potent oestrogen antagonist at concentrations exceeding 10nM. This result was demonstrable despite the fact that both 40HT and ICI 182780 have similar binding affinities for the ER (Wakeling et al., 1991) and is in accordance with the findings of previous in vitro studies with pure antioestrogens (Wakeling et al., 1991; Favoni et al., 1993) .
The results of preliminary experiments in which SFMpR was used showed that, at 1 FM concentrations, both 40HT and ICI 182780 reduced the CFE of MCF-7 cells to significantly below the level of untreated controls. These effects were considered to have most likely resulted from elevation of the CFE of controls by the oestrogenic activity of phenol red. However, in some of the subsequent experiments that were performed using SFMmF, high (0.1 -1.0 gM) concentrations of ICI 182780 continued to reduce the CFE of MCF-7 cells to below the level of controls from which all exogenous oestrogens, including phenol red, had been excluded.
These findings may be explained in three ways. Firstly, they may simply demonstrate antagonism by ICI 182780 of retained intracellular steroids carried over by the MCF-7 cells during transfer from stock monolayer culture in SCM into the Courtenay-Mills assay. Previous studies have shown that breast cancer cells can retain intracellular steroids for prolonged periods following transfer from oestrogen-containing to oestrogen-free growth conditions (Strobl & Lippman, 1979) . The potential confounding effects of this so-called 'steroid memory' might have been avoided in the present study by maintenance of the stock monolayer cultures of MCF-7 cells in SFMmF. However, this might potentially have selected out hormone-independent MCF-7 cell clones.
Secondly, the findings may have resulted from antagonism by ICI 182780 of other potential mitogens, including insulin and EGF, contained in the SFM formulation used in the present study to culture cells in the Courtenay-Mills assay. Conventional antioestrogens including tamoxifen have been reported to antagonise the mitogenic effects of peptide growth factors including insulin-like growth factor type 1 (IGF-1) and epidermal growth factor (EGF) in the absence of oestrogens Wosikowski et al., 1993) .
Finally, the findings may have been due to cytotoxic activity occurring at high concentrations of ICI 182780. Nonsteroidal antioestrogens, including 40HT, have previously been shown to cause specific ER-mediated cytotoxic effects at concentrations between 10 nM and 1 FuM (Bardon et al., 1987) and non-specific ER-independent cytotoxic effects at concentrations exceeding 5 gM (Green et al., 1981; Lippman et al., 1981) . The lack of activity of ICI 182780 in ER-negative Hs578T cells seen in the present study suggests that the antiproliferative effects of this agent in MCF-7 cells were ER dependent and were not due to non-specific cytotoxicity. (Roos et al., 1982; Darbre et al., 1984; Reddel & Sutherland, 1984; Katzenellenbogen et al., 1987; Thompson et al., 1989; Wakeling et al., 1989) but not by the pure antioestrogens ICI 164384 or ICI 182780 (Thompson et al., 1989; Wakeling et al., 1991) .
The experiments performed in the present study using primary cultures of tumour cells from malignant pleural effusions were designed to look for evidence of stimulation by 40HT of the clonogenic growth of cells taken directly from breast cancer patients who appeared to be tamoxifen resistant. In addition, the experiments were designed to evaluate the sensitivity of tumour cells from tamoxifenresistant patients to oestradiol and ICI 182780.
One disadvantage associated with the use of pleural effusions as sources of breast cancer cells in the present study was the relatively small number of suitable patients seen in the breast clinic with malignant effusions during the 14 month study period. Consequently, primary culture of metastatic cancer cells using the Courtenay-Mills assay could only be attempted in eight cases.
Of the eight pleural effusions cultured, six yielded tumour cells that successfully formed colonies in the CourtenayMills assay under serum-and phenol red-free culture conditions. The CFEs of the primary cultures under control conditions were highly variable, but were within the range of CFEs previously reported by Ottestad et al. (1988) for 237 primary or recurrent breast tumours cultured in the Courtenay-Mills assay using SCM.
The different responses to oestradiol and the two antioestrogens seen in the six successful primary cultures provide preliminary evidence to suggest that breast cancer cells from tamoxifen-resistant patients exhibit at least three patterns of in vitro hormone-responsiveness: (i) generalised hormone independence; (ii) continued sensitivity to oestradiol and to the antioestrogenic activity of ICI 182780 but overall resistance to 4OHT; and (iii) stimulation by oestradiol and 40HT and inhibition of both oestradiol-and 40HT-stimulated growth by ICI 182780. Although the results of these primary culture experiments must be viewed as preliminary because of the small patient numbers involved, it is noteworthy that four previous studies have found evidence of stimulation by tamoxifen of breast cancer cells cultured directly from patients (Simon et al., 1984b; Manni et al., 1985; Osborne et al., 1985; Nomura et al., 1990) .
It is concluded from this study that the Courtenay-Mills soft-agar clonogenic assay is suitable for investigating the effects of endocrine agents on the growth of established breast cancer cell lines and metastatic breast cancer cells taken directly from patients. At drug concentrations exceeding 10 nM, the novel steroidal antioestrogen, ICI 182780, exhibits a more complete and potent antioestrogenic effect than 40HT on colony formation by hormone-responsive breast cancer cells and, unlike 40HT, ICI 182780 exhibits no demonstrable agonist activity. Investigation of the effects of these agents in metastatic breast cancer cells taken from patients at the time of relapse on tamoxifen provides preliminary evidence to suggest that some patients may fail on tamoxifen therapy because of the oestrogenic activity of the parent drug and/or its metabolites and that treatment with a pure antioestrogen may be effective in patients with advanced breast cancer who appear to be resistant to tamoxifen.
A*bbiadow ER, oestrogen receptor, CFE, colony-forming efficncy; SCM, serum-containing growth medium; SFMpR, serumfree growth medium containing phenol red; SFMmF, serwm-free/ phenol red-free growth medium; 40HT, 4-hydroxytamoxifen; ICI 182780, 7{-[9-(4,4,5,5,5-pentafluoropentylsulhpinyl)nonyloestra-1,3,5, (I 0)triene-3, 17B diol.
